Latest Insider Transactions at Tff Pharmaceuticals, Inc. (TFFP)
This section provides a real-time view of insider transactions for Tff Pharmaceuticals, Inc. (TFFP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of TFF Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of TFF Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 03
2024
|
Catherine Chai Zon Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,583
+50.0%
|
-
|
|
Jul 03
2024
|
Harlan F Weisman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
27,480
+3.16%
|
-
|
|
Jul 03
2024
|
Thomas Braxton King Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,583
+50.0%
|
-
|
|
Jul 03
2024
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,165
+7.48%
|
-
|
|
Jul 03
2024
|
Zamaneh Mikhak Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,184
+6.55%
|
-
|
|
Jul 03
2024
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,184
+18.17%
|
-
|
|
Jul 03
2024
|
Brandi Roberts Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,165
+12.02%
|
-
|
|
Jul 03
2024
|
Robert S Mills Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,165
+5.08%
|
-
|
|
Aug 16
2023
|
Carlson Capital L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000
-0.02%
|
$0
$0.39 P/Share
|
|
Aug 15
2023
|
Carlson Capital L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
215,000
-4.07%
|
$0
$0.44 P/Share
|
|
Aug 15
2023
|
Zamaneh Mikhak Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
120,000
+47.06%
|
$0
$0.25 P/Share
|
|
Aug 15
2023
|
Robert S Mills Director |
BUY
Open market or private purchase
|
Direct |
40,000
+41.68%
|
$0
$0.25 P/Share
|
|
Aug 15
2023
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+35.92%
|
$0
$0.25 P/Share
|
|
Aug 15
2023
|
Brandi Roberts Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.25 P/Share
|
|
Aug 15
2023
|
Stephen Rocamboli Director |
BUY
Open market or private purchase
|
Direct |
20,000
+35.71%
|
$0
$0.25 P/Share
|
|
Aug 15
2023
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
600,000
+42.41%
|
$0
$0.25 P/Share
|
|
Mar 10
2023
|
Stephen Rocamboli Director |
BUY
Open market or private purchase
|
Direct |
13,000
+44.83%
|
$0
$0.8 P/Share
|
|
Mar 10
2023
|
Zamaneh Mikhak Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$0
$0.82 P/Share
|
|
Mar 10
2023
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
150,000
+41.14%
|
$0
$0.88 P/Share
|
|
Mar 10
2023
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,000
+43.36%
|
$0
$0.79 P/Share
|
|
Dec 15
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+43.62%
|
$50,000
$1.06 P/Share
|
|
Nov 22
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Direct |
43,470
+23.25%
|
$43,470
$1.15 P/Share
|
|
Sep 29
2022
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
40,255
-100.0%
|
$161,020
$4.29 P/Share
|
|
Sep 29
2022
|
Randy H Thurman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,255
+50.0%
|
$80,510
$2.5 P/Share
|
|
May 20
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
4,615
+24.0%
|
$23,075
$5.5 P/Share
|
|
May 18
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+20.0%
|
$12,500
$5.12 P/Share
|
|
May 17
2022
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
425
+10.37%
|
$1,700
$4.83 P/Share
|
|
May 17
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
24,600
+18.33%
|
$123,000
$5.08 P/Share
|
|
May 16
2022
|
Stephen Rocamboli Director |
BUY
Open market or private purchase
|
Direct |
3,000
+13.81%
|
$12,000
$4.54 P/Share
|
|
May 16
2022
|
Glenn R. Mattes President and CEO |
BUY
Open market or private purchase
|
Direct |
16,000
+30.77%
|
$64,000
$4.78 P/Share
|
|
May 16
2022
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+27.78%
|
$5,000
$4.4 P/Share
|
|
May 16
2022
|
Harlan F Weisman President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+25.0%
|
$10,000
$4.74 P/Share
|
|
May 16
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
85,000
+50.0%
|
$340,000
$4.86 P/Share
|
|
Apr 04
2022
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Indirect |
542,000
+28.6%
|
$3,252,000
$6.66 P/Share
|
|
Sep 16
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$7,000
$7.3 P/Share
|
|
Sep 16
2021
|
Glenn R. Mattes President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+33.33%
|
$70,000
$7.1 P/Share
|
|
May 19
2021
|
Malcolm Fairbairn Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$80,000
$8.95 P/Share
|
|
May 18
2021
|
Randy H Thurman Director |
BUY
Open market or private purchase
|
Direct |
1,050
+50.0%
|
$9,450
$9.4 P/Share
|
|
Mar 26
2021
|
Lung Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
715,000
-24.24%
|
$10,010,000
$14.0 P/Share
|
|
Mar 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$85,000
$17.05 P/Share
|
|
Mar 15
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Mar 15
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-83.33%
|
$850,000
$17.04 P/Share
|
|
Mar 15
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.45%
|
$100,000
$2.5 P/Share
|
|
Mar 15
2021
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
20,006
-56.0%
|
$320,096
$16.85 P/Share
|
|
Mar 15
2021
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,006
+22.72%
|
$60,018
$3.75 P/Share
|
|
Feb 16
2021
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-83.33%
|
$80,000
$16.82 P/Share
|
|
Feb 16
2021
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+45.45%
|
$10,000
$2.5 P/Share
|
|
Feb 16
2021
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
40,000
-80.0%
|
$640,000
$16.82 P/Share
|
|
Feb 16
2021
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+44.44%
|
$80,000
$2.5 P/Share
|
|
Feb 10
2021
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
700
-4.2%
|
$14,000
$20.16 P/Share
|